Pretherapeutic Identification of High Risk AML Patients
- Eight patient and clinical chemistry parameters, one overall
survival (OS) indicator for clinical outcome,
25 cytogenetic abnormalities and 36 flow cytometric
immunophenotype parameters at diagnosis were available for classification.
One color indirect (FITC-F(ab')2 fragments
immunophenotypes were used throughout the study for reasons
of compatibility with the early determinations of the multicenter trial.
last Update: Jun 03,2022
first display: Mar 31,2003